{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:58:25Z","timestamp":1791907105943,"version":"4.3.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>\n                                 <jats:sup>18<\/jats:sup>F-FDG PET\/CT plays a crucial role in the evaluation and management of pediatric classic Hodgkin lymphoma (cHL). In addition to visual assessment, quantitative parameters also have prognostic value. This study aimed to investigate the prognostic significance of PET parameters, with a particular focus on the changes observed in these parameters after 2 cycles of chemotherapy, in pediatric cHL patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>The study was designed as a single-center, retrospective. A total of 198 pediatric cHL patients who underwent baseline and post-2-cycle chemotherapy interim <jats:sup>18<\/jats:sup>F-FDG PET\/CT imaging between January 2019 and October 2023 were included in the study. Four different segmentation methods (%41 SUVmax, %42 SUVmax, mediastinal SUVmax, and liver SUVmax) were applied. Quantitative parameters, including metabolic tumor volume (MTV), total lesion glycolysis (TLG), and their changes after 2 chemotherapy cycles (\u0394MTV, \u0394TLG), were evaluated for each segmentation method. The prognostic significance of these parameters for progression-free survival (PFS) was assessed using Cox regression analysis, while survival differences based on optimal cutoff values were evaluated using Kaplan-Meier analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 48 pediatric cHL patients (32 males, median age: 12\u00a0y) met the inclusion criteria. During a median follow-up of 21 months (range: 5\u201352\u00a0mo), disease progression was observed in 22.9% of the patients (n=11). Baseline <jats:sup>18<\/jats:sup>F-FDG PET\/CT quantitative parameters did not show significant differences between progression and nonprogression groups. However, on interim <jats:sup>18<\/jats:sup>F-FDG PET\/CT, higher values of quantitative parameters from 3 segmentation methods (%41 SUVmax, %42 SUVmax, and mediastinal SUVmax) and lower postchemotherapy reductions in \u0394SUVmax, \u0394MTV<jats:sub>(41)<\/jats:sub>, \u0394MTV<jats:sub>(42)<\/jats:sub>, \u0394TLG<jats:sub>(41)<\/jats:sub>, and \u0394TLG<jats:sub>(med)<\/jats:sub> were associated with poor PFS. In multivariate Cox regression analysis, i-SUVmax (Hazard ratio, HR: 1.20, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) and \u0394MTV<jats:sub>(41)<\/jats:sub> (HR: 0.965, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.007) were identified as independent risk factors for PFS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Interim <jats:sup>18<\/jats:sup>F-FDG PET parameters and postchemotherapy changes demonstrated significant prognostic value. Quantitative evaluation beyond visual assessment may contribute to risk-adapted and personalized treatment approaches in pediatric cHL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005874","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T23:27:02Z","timestamp":1743722822000},"page":"e407-e416","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic Impact of Quantitative Changes Between Baseline and Interim 18F-FDG PET\/CT in Pediatric Classic Hodgkin Lymphoma"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6440-4219","authenticated-orcid":false,"given":"Mehmet O\u011fuz","family":"Kartal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University of Health Sciences, Ankara Bilkent City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fenur Sinem","family":"Kartal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Health Sciences, Ankara Bilkent City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3474-5070","authenticated-orcid":false,"given":"Bur\u00e7ak","family":"Kurucu","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Etlik City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-6522","authenticated-orcid":false,"given":"Derya","family":"\u00d6zy\u00f6r\u00fck","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University of Health Sciences, Ankara Bilkent City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcrses","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University of Health Sciences, Dr. Sami Ulus Children\u2019s Hospital, Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nedim C.M.","family":"G\u00fclaldi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Health Sciences, Ankara Bilkent City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood-2015-07-641035","article-title":"Hodgkin lymphoma in children and adolescents: improving the therapeutic index","volume":"126","author":"Kelly","year":"2015","journal-title":"Blood"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2014.59.4853","article-title":"Pediatric Hodgkin lymphoma","volume":"33","author":"Mauz-K\u00f6rholz","year":"2015","journal-title":"JCO"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1002\/cncr.31519","article-title":"Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children\u2019s Oncology Group","volume":"124","author":"Keller","year":"2018","journal-title":"Cancer"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ijrobp.2016.07.015","article-title":"Predictive factor analysis of response-adapted radiation therapy for chemotherapy-sensitive apediatric Hodgkin lymphoma: analysis of the Children\u2019s Oncology Group AHOD 0031 Trial","volume":"96","author":"Charpentier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1055\/s-0035-1559664","article-title":"Pediatric nodular lymphocyte-predominant Hodgkin lymphoma: treatment tecommendations of the GPOH-HD Study Group","volume":"227","author":"Mauz-K\u00f6rholz","year":"2015","journal-title":"Klin Padiatr"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"733","DOI":"10.6004\/jnccn.2021.0027","article-title":"Pediatric Hodgkin lymphoma, Version 3.2021","volume":"19","author":"Flerlage","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12885-018-4432-4","article-title":"Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin\u2019s lymphoma","volume":"18","author":"Rogasch","year":"2018","journal-title":"BMC Cancer"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"e29212","DOI":"10.1002\/pbc.29212","article-title":"Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031","volume":"68","author":"Milgrom","year":"2021","journal-title":"Pediatric Blood & Cancer"},{"key":"R10-20250619","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.3390\/jcm11206223","article-title":"Prospective evaluation of different methods for volumetric analysis on [18F]FDG PET\/CT in pediatric Hodgkin lymphoma","volume":"11","author":"Lopci","year":"2022","journal-title":"JCM"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s00259-024-06643-8","article-title":"Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin\u2019s lymphoma","volume":"51","author":"Yadgarov","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21608\/egyjnm.2023.218109.1078","article-title":"Prognostic value of baseline and interim volume based PET parameters in prediction of early therapy response and survival in pediatric patients with bulky and advanced HL","volume":"26","author":"Ali","year":"2023","journal-title":"Egyptian J Nucl Med"},{"issue":"S6","key":"R13-20250619","doi-asserted-by":"crossref","first-page":"e30580","DOI":"10.1002\/pbc.30580","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Hodgkin lymphoma","volume":"70","author":"Castellino","year":"2023","journal-title":"Pediatric Blood & Cancer"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JCO"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"JCO"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1470-2045(23)00019-0","article-title":"Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study","volume":"24","author":"Mauz-K\u00f6rholz","year":"2023","journal-title":"Lancet Oncol"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1053\/j.semnuclmed.2017.01.001","article-title":"Current role of FDG-PET in pediatric Hodgkin\u2019s lymphoma","volume":"47","author":"Kluge","year":"2017","journal-title":"Semin Nucl Med"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1182\/blood-2023-189991","article-title":"Validation of Childhood Hodgkin International Prognostic Score (CHIPS) for predicting event-free survival in intermediate and high-risk Hodgkin lymphoma","volume":"142","author":"Marks","year":"2023","journal-title":"Blood"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-022-09758-z","article-title":"Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma \u2013 Data from the prospective, multicenter phase III HD16 trial","volume":"22","author":"van Heek","year":"2022","journal-title":"BMC Cancer"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","article-title":"Early interim 18F-FDG PET in Hodgkin\u2019s lymphoma: evaluation on 304 patients","volume":"39","author":"Zinzani","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"e27539","DOI":"10.1002\/pbc.27539","article-title":"Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET \u2265 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial","volume":"66","author":"Kurch","year":"2019","journal-title":"Pediatric Blood & Cancer"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00259-018-3937-z","article-title":"Ultra-early response assessment in lymphoma treatment: [18F]FDG PET\/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment","volume":"45","author":"Mayerhoefer","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.19162","article-title":"Baseline circulating tumour DNA and interim PET predict response in relapsed\/refractory classical Hodgkin lymphoma","volume":"204","author":"Calabretta","year":"2024","journal-title":"Br J Haematol"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/1078-0432.CCR-20-3303","article-title":"Early Response to first-line anti\u2013PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial","volume":"27","author":"Voltin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cancers7010287","article-title":"FDG-PET response prediction in pediatric Hodgkin\u2019s lymphoma: impact of metabolically defined tumor volumes and individualized SUV measurements on the positive predictive value","volume":"7","author":"Hussien","year":"2015","journal-title":"Cancers"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00259-014-2783-x","article-title":"Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma","volume":"41","author":"Kanoun","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:00:17Z","timestamp":1750341617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005874","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"2024-12-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}